Literature DB >> 21901637

Dealing with initial inconclusive serological results for chronic Chagas disease in clinical practice.

J S Lapa1, R M Saraiva, A M Hasslocher-Moreno, I Georg, A S Souza, S S Xavier, P E A A do Brasil.   

Abstract

Most guidelines for Chagas disease recommend the performance of two serological tests in order to detect it. However, inconclusive results may arise from this strategy. The aim was to describe whether serological follow-up together with the patient's clinical characteristics could clarify the outcome of patients with initial inconclusive test results. In this retrospective case series, all results of Chagas disease serological tests and outpatient visits recorded from 2004 to 2008 were screened for inclusion. The inclusion criterion was clinical suspicion of chronic Chagas disease and the exclusion criteria were previous diagnosis of Chagas disease, suspicion of acute Chagas disease, and serological tests with no corresponding medical evaluation. A total of 1,732 patients were analyzed. Chronic Chagas disease prevalence was 21.1%. After the initial set of serological tests, 2.9% of patients had inconclusive test results. Most of these patients had definite diagnosis after clinical follow-up and the repetition of serological tests in a new blood sample. Loss to follow-up while partaking in the diagnostic investigation reached 17.7%. The prevalence of initial inconclusive serological tests for chronic Chagas disease is low. Clinical evaluations and follow-up clarify the definite diagnosis. Noncompliance to follow-up is a frequent problem. Strategies to reduce inconclusive results and noncompliance are discussed.

Entities:  

Mesh:

Year:  2011        PMID: 21901637     DOI: 10.1007/s10096-011-1393-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

1.  [Brazilian Consensus on Chagas disease].

Authors: 
Journal:  Rev Soc Bras Med Trop       Date:  2005       Impact factor: 1.581

2.  The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region.

Authors:  Marianne Pirard; Naomi Iihoshi; Marleen Boelaert; Paulino Basanta; Freddy López; Patrick Van der Stuyft
Journal:  Transfusion       Date:  2005-04       Impact factor: 3.157

3.  Evidence of Chagas disease in seronegative Brazilian patients with megaesophagus.

Authors:  Angelica M Batista; Camila Aguiar; Eros A Almeida; Maria E Guariento; Jamiro S Wanderley; Sandra C B Costa
Journal:  Int J Infect Dis       Date:  2010-09-15       Impact factor: 3.623

4.  Household risk factors for Trypanosoma cruzi seropositivity in two geographic regions of Ecuador.

Authors:  Carla L Black; Sofia Ocaña; Diana Riner; Jaime A Costales; Mauricio S Lascano; Santiago Davila; Laura Arcos-Teran; J Richard Seed; Mario J Grijalva
Journal:  J Parasitol       Date:  2007-02       Impact factor: 1.276

5.  Socioepidemiological screening of serologically ineligible blood donors due to Chagas disease for the definition of inconclusive cases.

Authors:  Márcia M Ferreira-Silva; Gilberto A Pereira; Eliane Lages-Silva; Helio Moraes-Souza
Journal:  Mem Inst Oswaldo Cruz       Date:  2010-09       Impact factor: 2.743

6.  Inconclusive results in conventional serological screening for Chagas' disease in blood banks: evaluation of cellular and humoral response.

Authors:  Celia Regina Furuchó; Eufrozina S Umezawa; Igor Almeida; Vera L Freitas; Rita Bezerra; Elisabete V Nunes; Maria C Sanches; Cristina M Guastini; Antonio R Teixeira; Maria A Shikanai-Yasuda
Journal:  Trop Med Int Health       Date:  2008-10-28       Impact factor: 2.622

7.  Household prevalence of seropositivity for Trypanosoma cruzi in three rural villages in northwest Argentina: environmental, demographic, and entomologic associations.

Authors:  R E Gürtler; R Chuit; M C Cécere; M B Castañera; J E Cohen; E L Segura
Journal:  Am J Trop Med Hyg       Date:  1998-11       Impact factor: 2.345

8.  Risk factors for Trypanosoma cruzi human infection in Barinas State, Venezuela.

Authors:  M Dora Feliciangeli; Maria J Sánchez-Martín; Benny Suárez; Rosalba Marrero; Annhymariet Torrellas; Arturo Bravo; Mehudy Medina; Cinda Martínez; Mayeli Hernandez; Neidi Duque; José Toyo; Roberto Rangel
Journal:  Am J Trop Med Hyg       Date:  2007-05       Impact factor: 2.345

9.  Risk factors for Trypanosoma cruzi infection among blood donors in central Brazil.

Authors:  C M Martelli; A L Andrade; S A Silva; F Zicker
Journal:  Mem Inst Oswaldo Cruz       Date:  1992 Jul-Sep       Impact factor: 2.743

10.  Use of a questionnaire to identify potential blood donors at risk for infection with Trypanosoma cruzi.

Authors:  M D Appleman; I A Shulman; S Saxena; L V Kirchhoff
Journal:  Transfusion       Date:  1993-01       Impact factor: 3.157

View more
  10 in total

1.  Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?

Authors:  Alba Abras; Montserrat Gállego; Teresa Llovet; Silvia Tebar; Mercedes Herrero; Pere Berenguer; Cristina Ballart; Carmen Martí; Carmen Muñoz
Journal:  J Clin Microbiol       Date:  2016-04-06       Impact factor: 5.948

2.  Impact of pharmaceutical care on the quality of life of patients with heart failure due to chronic Chagas disease: Randomized clinical trial.

Authors:  Mayara da Costa Chambela; Mauro Felippe Felix Mediano; Fernanda Martins Carneiro; Roberto Rodrigues Ferreira; Mariana Caldas Waghabi; Verônica Gonçalves Mendes; Luciano de Souza Oliveira; Marcelo Teixeira de Holanda; Andréa Silvestre de Sousa; Andréa Rodrigues da Costa; Sérgio Salles Xavier; Gilberto Marcelo Sperandio da Silva; Roberto Magalhães Saraiva
Journal:  Br J Clin Pharmacol       Date:  2019-11-27       Impact factor: 4.335

3.  TGF-β Polymorphisms Are a Risk Factor for Chagas Disease.

Authors:  Roberto Rodrigues Ferreira; Fabiana da Silva Madeira; Gabriel Farias Alves; Mayara da Costa Chambela; Eduardo de Oliveira Vaz Curvo; Aline Dos Santos Moreira; Renata Almeida de Sá; Leila Mendonça-Lima; Pedro Hernan Cabello; Sabine Bailly; Jean-Jacques Feige; Tania Cremonini Araujo-Jorge; Roberto Magalhães Saraiva; Mariana Caldas Waghabi
Journal:  Dis Markers       Date:  2018-02-18       Impact factor: 3.434

4.  Evaluation of the Elecsys Chagas Assay for Detection of Trypanosoma cruzi-Specific Antibodies in a Multicenter Study in Europe and Latin America.

Authors:  Maria Delmans Flores-Chavez; Vittorio Sambri; Volkmar Schottstedt; Fernando Aparicio Higuera-Escalante; Dieter Roessler; Monica Chaves; Tina Laengin; Alfredo Martinez; Bernhard Fleischer
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

5.  Ageing with Chagas disease: an overview of an urban Brazilian cohort in Rio de Janeiro.

Authors:  Alexandre Gomes Vizzoni; Margareth Catoia Varela; Luiz Henrique Conde Sangenis; Alejandro Marcel Hasslocher-Moreno; Pedro Emmanuel Alvarenga Americano do Brasil; Roberto Magalhães Saraiva
Journal:  Parasit Vectors       Date:  2018-06-19       Impact factor: 3.876

6.  Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study.

Authors:  Alejandro M Hasslocher-Moreno; Roberto M Saraiva; Luiz H C Sangenis; Sergio S Xavier; Andrea S de Sousa; Andrea R Costa; Marcelo T de Holanda; Henrique H Veloso; Fernanda S N S Mendes; Filipe A C Costa; Marcio N Boia; Pedro E A A Brasil; Fernanda M Carneiro; Gilberto M Sperandio da Silva; Mauro F F Mediano
Journal:  EClinicalMedicine       Date:  2020-12-23

7.  Evaluation of Nine Commercial Serological Tests for the Diagnosis of Human Hepatic Cyst Echinococcosis and the Differential Diagnosis with Other Focal Liver Lesions: A Diagnostic Accuracy Study.

Authors:  Francesca Tamarozzi; Silvia Stefania Longoni; Ambra Vola; Monica Degani; Stefano Tais; Eleonora Rizzi; Marco Prato; Salvatore Scarso; Ronaldo Silva; Enrico Brunetti; Zeno Bisoffi; Francesca Perandin
Journal:  Diagnostics (Basel)       Date:  2021-01-25

8.  Blood DNA methylation marks discriminate Chagas cardiomyopathy disease clinical forms.

Authors:  Pauline Brochet; Barbara Ianni; João P S Nunes; Amanda F Frade; Priscila C Teixeira; Charles Mady; Ludmila R P Ferreira; Andreia Kuramoto; Cristina W Pissetti; Bruno Saba; Darlan D S Cândido; Fabrício Dias; Marcelo Sampaio; José A Marin-Neto; Abílio Fragata; Ricardo C F Zaniratto; Sergio Siqueira; Giselle D L Peixoto; Vagner O C Rigaud; Paula Buck; Rafael R Almeida; Hui Tzu Lin-Wang; André Schmidt; Martino Martinelli; Mario H Hirata; Eduardo Donadi; Virmondes Rodrigues Junior; Alexandre C Pereira; Jorge Kalil; Lionel Spinelli; Edecio Cunha-Neto; Christophe Chevillard
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

9.  Highly discordant serology against Trypanosoma cruzi in central Veracruz, Mexico: role of the antigen used for diagnostic.

Authors:  Daniel Guzmán-Gómez; Aracely López-Monteon; María de la Soledad Lagunes-Castro; Carolina Álvarez-Martínez; Manuel Jesús Hernández-Lutzon; Eric Dumonteil; Angel Ramos-Ligonio
Journal:  Parasit Vectors       Date:  2015-09-17       Impact factor: 3.876

Review 10.  Commercial enzyme-linked immunosorbent assay versuspolymerase chain reaction for the diagnosis of chronic Chagas disease: a systematic review and meta-analysis.

Authors:  Pedro Emmanuel Alvarenga Americano do Brasil; Rodolfo Castro; Liane de Castro
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-01       Impact factor: 2.743

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.